Clinical Trials Logo

Filter by:
NCT ID: NCT03284879 Completed - Psoriasis Clinical Trials

Post-Marketing Surveillance Study of OTEZLA

Start date: September 5, 2017
Phase:
Study type: Observational

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch

NCT ID: NCT03284177 Completed - Clinical trials for Gastroesophageal Reflux Disease

A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients

Start date: October 31, 2017
Phase: Phase 2
Study type: Interventional

To investigate the safety of C13-CAC and the relationship among C13-CAC breath test, gastric pH, and the improvement of symptoms by switching PPI in PPI resistant GERD patients

NCT ID: NCT03283085 Completed - Ulcerative Colitis Clinical Trials

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Start date: February 27, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)

NCT ID: NCT03282019 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Study of Long-term HFNC for COPD Patients With HOT

FLOCOP
Start date: September 6, 2017
Phase: N/A
Study type: Interventional

This is a prospective, randomized parallel study for evaluation of the efficacy and safety of long-term nocturnal high-flow nasal cannula therapy (HFNC: with the myAIRVO2 as HFNC in this study) in stable COPD patients with the global initiative for chronic obstructive lung disease (GOLD) stage 2-4, PaCO2 >= 45 Torr and hypercapnia who require home oxygen therapy (HOT) using COPD exacerbation (Moderate or Severe).

NCT ID: NCT03281304 Terminated - Ulcerative Colitis Clinical Trials

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Start date: November 16, 2017
Phase: Phase 4
Study type: Interventional

This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.

NCT ID: NCT03281005 Completed - Clinical trials for Retinitis Pigmentosa

Development of Visual Function Evaluation Method

Start date: November 1, 2017
Phase:
Study type: Observational

The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient

NCT ID: NCT03280264 Completed - Clinical trials for Primary Hyperparathyroidism

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Start date: August 30, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

NCT ID: NCT03280030 Completed - Clinical trials for Acute Myeloid Leukemia

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Start date: April 6, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).

NCT ID: NCT03278080 Completed - Clinical trials for Healthy Participants

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1

Start date: September 22, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to set an optimal measurement time for assessing driving ability in a driving simulator in healthy volunteers.

NCT ID: NCT03277105 Completed - Multiple Myeloma Clinical Trials

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Start date: October 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).